NIKKEI 225
26,677.80 -70.34 (-0.26%) HANG SENG
20,171.27 +59.17 (+0.29%) CRUDE OIL
110.77 +0.44 (+0.40%) GOLD FUTURES
1,852.10 +5.80 (+0.31%) DOW
32,120.28 +191.66 (+0.60%) BTC-GBP
23,487.87 -183.26 (-0.77%)
Merus N.V. (MRUS)
| Previous close | 16.22 |
| Open | 16.39 |
| Bid | 6.60 x 900 |
| Ask | 19.88 x 2200 |
| Day's range | 15.91 - 17.17 |
| 52-week range | 14.65 - 33.09 |
| Volume | |
| Avg. volume | 219,109 |
| Market cap | 716.883M |
| Beta (5Y monthly) | 1.01 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Globe Newswire
Merus to Present at the H.C. Wainwright Global Investment Conference
UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will present at the H.C. Wainwright Global Investment Conference. The webcast of the presentation will be available on-demand starting on May 24, 2022 at 7:00 a.m. ET and will be con
- Globe Newswire
Merus Announces Financial Results for the First Quarter 2022 and Provides Business Update
- Zenocutuzumab clinical abstract selected for oral presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting- Company to host investor call on Sunday, June 5 at 6:00 p.m. CT- Clinical data update of petosemtamab (Peto) and MCLA-129 planned for second half of 2022 UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 09, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we”, or “our”), a clinical-stage oncology company developing innovative, ful
- Globe Newswire
Zenocutuzumab Clinical Abstract Selected for Oral Presentation at the 2022 American Society of Clinical Oncology Annual Meeting
UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 27, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the selection of an abstract for oral presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, being held in Chicago, Illinois on June 3-7, 2022. The presentation will highlight upd
